Compare Adobe Systems Inc (ADBE) vs Citius Pharmaceuticals Inc (CTXR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adobe Systems Inc vs Citius Pharmaceuticals Inc — how do they compare? Adobe Systems Inc trades at $262.23 (market cap $108.50B), while Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M). The key difference: Adobe Systems Inc is far larger — about 5792.8× Citius Pharmaceuticals Inc's market cap, and Adobe Systems Inc is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| ADBE | CTXR | |
|---|---|---|
Market Cap | $108.50B | $18.73M |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $367.46 | $1.82 |
52-Week Low | $193.41 | $0.48 |
Enterprise Value | $109.94B | $14.95M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe (ADBE) trades at $272.96, up 2.92% today, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $5.96 exceeding the $5.82 estimate. Revenue grew to $23.77B in 2025, and net income margin improved to 28.69%. However, the stock faces headwinds from AI competition fears and a recent 52-week low, as noted by Citi on April 10, 2026.
The outlook is mixed: robust fundamentals and a 49.2% buy rating from analysts support upside potential, with a consensus price target of $248.86. Key risks include generative AI disruption and CEO transition uncertainty. Investors should weigh strong cash flows against competitive pressures in the software sector.
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →
